Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Karen W Verhoeven-Adema"'
Autor:
Nanda Horeweg, Stefan Kommoss, Ludy C.H.W. Lutgens, Katrien Vandecasteele, Marlies E. Nowee, Remi A. Nout, C. Gillham, Bastiaan G Wortman, F. Koppe, Hetty A. van den Berg, Tjalling Bosse, David Cibula, Karen W Verhoeven-Adema, Annerie Slot, Hein Putter, Cyrus Chargari, Ina M. Jürgenliemk-Schulz, Veronique L M A Coen, Aleida G Zwanenburg, Hans W. Nijman, Carien L. Creutzberg, Elzbieta van der Steen-Banasik, Tanja C. Stam, G Henrieke Westerveld, Anne Sophie V M van den Heerik, Wilbert B. van den Hout, Jan Willem M. Mens, An Snyers, Moritz Hamann, Stefan Bijmolt
Publikováno v:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020(30), 2002-2007. BMJ Publishing Group
International journal of gynecological cancer, 30(12), 2002-2007. Wolters Kluwer Health
International Journal of Gynecological Cancer, 30, 12, pp. 2002-2007
International Journal of Gynecological Cancer, 30(12), 2002-2007. BMJ Publishing Group
International Journal of Gynecological Cancer
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
International Journal of Gynecological Cancer, 30, 2002-2007
International Journal of Gynecological Cancer, 30(12), 2002-2007. LIPPINCOTT WILLIAMS & WILKINS
International journal of gynecological cancer, 30(12), 2002-2007. Wolters Kluwer Health
International Journal of Gynecological Cancer, 30, 12, pp. 2002-2007
International Journal of Gynecological Cancer, 30(12), 2002-2007. BMJ Publishing Group
International Journal of Gynecological Cancer
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
International Journal of Gynecological Cancer, 30, 2002-2007
International Journal of Gynecological Cancer, 30(12), 2002-2007. LIPPINCOTT WILLIAMS & WILKINS
BackgroundVaginal brachytherapy is currently recommended as adjuvant treatment in patients with high-intermediate risk endometrial cancer to maximize local control and has only mild side effects and no or limited impact on quality of life. However, t
Autor:
Carien L. Creutzberg, Petronella B. Ottevanger, Annamaria Ferrero, Luis Souhami, Pearly Khaw, GH Westerveld, Diane Provencher, Gillian Thomas, Jan Pyman, V. Do, Annerie Slot, C Davidson, G. Wilson, Stephanie M. de Boer, Peter Hoskin, C M McLachlin, Michael A. Quinn, Deborah Gregory, Remi A. Nout, Hans W. Nijman, J.J. Jobsen, Tanja C. Stam, Vincent T.H.B.M. Smit, K Whitmarsh, Paul Bessette, Roy F.P.M. Kruitwagen, W Taylor, Dionyssios Katsaros, Chantal Hanzen, Henry C Kitchener, M McCormack, Prafull Ghatage, Dominique Berton-Rigaud, J.W.M. Mens, Melanie E Powell, Elisabeth Pras, Jonathan A. Ledermann, Karen W Verhoeven-Adema, Harmen Hollema, Andrea Lissoni, Linda Mileshkin, Anjana Anand, Amanda Feeney, Sergio Gribaudo, Marie-Helene Baron, R Allerton, Hein Putter, Colin D. Johnson, P. Symonds, Ina M. Jürgenliemk-Schulz, Romerai D'Amico, Ilka Kolodziej, M Adusumalli, Naveena Singh, G Artioli, An Snyers, R Wade, Christine Haie-Meder, Roldano Fossati, Nicole Tubiana-Mathieu, Anthony Fyles, Silvestro Carinelli, Anne Capp, Alexandra J. Stewart, Kaj De Winter, B. van Triest, L.C.H.W. Lutgens, Susan Brooks, E. Van der Steen-Banasik, Pierre Duvillard, Pvc Rittenberg, Alessandro Colombo
Publikováno v:
Lancet Oncology, 20, 1273-1285
Lancet oncology, 20(9), 1273-1285. Elsevier Science
The Lancet Oncology, 20(9), 1273-1285
PORTEC study group 2019, ' Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 20, no. 9, pp. 1273-1285 . https://doi.org/10.1016/S1470-2045(19)30395-X
The Lancet Oncology
Lancet Oncology, 20(9), 1273-1285. ELSEVIER SCIENCE INC
Lancet Oncology, 20, 9, pp. 1273-1285
Lancet oncology, 20(9), 1273-1285. Elsevier Science
The Lancet Oncology, 20(9), 1273-1285
PORTEC study group 2019, ' Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 20, no. 9, pp. 1273-1285 . https://doi.org/10.1016/S1470-2045(19)30395-X
The Lancet Oncology
Lancet Oncology, 20(9), 1273-1285. ELSEVIER SCIENCE INC
Lancet Oncology, 20, 9, pp. 1273-1285
BACKGROUND:The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate patterns of recurrence and
Autor:
Ina M. Jürgenliemk-Schulz, Ludy C.H.W. Lutgens, Marie Helene Baron, V. Do, Karen W Verhoeven-Adema, C. Post, Nelleke Ottevanger, Carien L. Creutzberg, Christine Haie-Meder, Jonathan A. Ledermann, Susan Brooks, Geraldine Goss, Linda Mileshkin, Anthony Fyles, Paul Bessette, Melanie E Powell, Roldano Fossati, Mary McCormack, Stephanie M. de Boer, Henry C Kitchener, Andrea Lissoni, Alexandra Leary, Vincent T.H.B.M. Smit, Romerai D'Amico, Amanda Feeney, Dionyssios Katsaros, Remi A. Nout, Hans W. Nijman, Hein Putter, Prafull Ghatage, Pearly Khaw
Publikováno v:
International Journal of Radiation Oncology-Biology-Physics, 109(4), 975-986. ELSEVIER SCIENCE INC
International Journal of Radiation Oncology, Biology, Physics, 109, 975-986
International Journal of Radiation Oncology Biology Physics, 109(4), 975-986. Elsevier Science
International Journal of Radiation Oncology, Biology, Physics, 109(4), 975-986. ELSEVIER SCIENCE INC
International Journal of Radiation Oncology, Biology, Physics, 109, 4, pp. 975-986
International journal of radiation oncology, biology, physics, 109(4), 975-986. Elsevier
International Journal of Radiation Oncology, Biology, Physics, 109, 975-986
International Journal of Radiation Oncology Biology Physics, 109(4), 975-986. Elsevier Science
International Journal of Radiation Oncology, Biology, Physics, 109(4), 975-986. ELSEVIER SCIENCE INC
International Journal of Radiation Oncology, Biology, Physics, 109, 4, pp. 975-986
International journal of radiation oncology, biology, physics, 109(4), 975-986. Elsevier
Contains fulltext : 232064.pdf (Publisher’s version ) (Open Access) PURPOSE: The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival with chemoradiation therapy versus pelvic radiation t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2798f409593ab83be7f21b7d7f100a58
http://www.redjournal.org/article/S0360301620344473/pdf
http://www.redjournal.org/article/S0360301620344473/pdf
Autor:
Remi A. Nout, Hans W. Nijman, Pearly Khaw, Paul Bessette, S. M. de Boer, Carien L. Creutzberg, Petronella B. Ottevanger, D. Katsaros, Christine Haie-Meder, Romerai D'Amico, Marie-Helene Baron, Vthbm Smit, Jonathan A. Ledermann, Amanda Feeney, Anthony Fyles, C. Post, M. E. Powell, L.C.H.W. Lutgens, Susan Brooks, Hein Putter, Karen W Verhoeven-Adema, I.M. Jürgenliemk-Schulz, Henry C Kitchener, Linda Mileshkin
Publikováno v:
Radiotherapy and Oncology. 152:S199-S200
Autor:
Jonathan A. Ledermann, Anthony Fyles, Remi A. Nout, Hans W. Nijman, Karen W Verhoeven-Adema, Linda Mileshkin, Carien L. Creutzberg, Petronella B. Ottevanger, Christine Haie-Meder, M. E. Powell, I.M. Jürgenliemk-Schulz, Ilka Kolodziej, S. M. de Boer, Henry C Kitchener, Silvestro Carinelli, Naveena Singh, Pearly Khaw, Paul Bessette, G. Wilson, Dionyssios Katsaros, Hein Putter, L.C.H.W. Lutgens, Alessandro Colombo, Marie-Helene Baron, Vincent T.H.B.M. Smit
Publikováno v:
Radiotherapy and Oncology. 127:S171-S172
Autor:
Carien L. Creutzberg, Petronella B. Ottevanger, Stephanie M. de Boer, Melanie E Powell, Pearly Khaw, Henry C Kitchener, Vincent T.H.B.M. Smit, Hein Putter, Karen W Verhoeven-Adema, Remi A. Nout, Hans W. Nijman, Jonathan A. Ledermann, Linda Mileshkin, Alessandro Colombo, Anthony Fyles, Dionyssios Katsaros, Roy F.P.M. Kruitwagen, Marie-Helene Baron, Paul Bessette, Christine Haie-Meder
Publikováno v:
Journal of Clinical Oncology. 33:5501-5501
5501 Background: PORTEC-3 is an intergroup trial investigating survival improvement with adjuvant chemotherapy given during and after pelvic RT (CTRT) versus RT alone (RT) for women with high-risk ...